Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
Login My Member Benefits Archives Research Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    ×
  • Subscribe
Enter stock ticker or keyword
×
5 Ways to Beat the Fed (and Crush Inflation)

Email this Article

Send with mail | ahoo instead.
Required Needs to be a valid email
Required Needs to be a valid email
Biotech Stocks Are Ready to Break Out, So Grab These 3 Deals Now
https://mney.co/2JIjbJZ
Required Please enter the correct value.
Twitter
Stocks: CELG, JAZZ, SHPG

Biotech Stocks Are Ready to Break Out, So Grab These 3 Deals Now

By Stephen Mack, Associate Editor, Money Morning • May 2, 2018

Start the conversation

Comment on This Story Click here to cancel reply.

Or to contact Money Morning Customer Service, click here.

Your email address will not be published. Required fields are marked *

Some HTML is OK

When it comes to biotech stocks, it's time to separate the signal from the noise.

It's been a rough year so far for the sector. The iShares Nasdaq Biotechnology ETF (Nasdaq: IBB) is down 12.7% from its peak in late January.

Biotech

But that has less to do with the value of this sector and more to do with market overreactions to minor setbacks and rumors. As a result, some of the best biotech stocks on the market have been pushed well below their fundamental value based on assets and earnings.

And when you consider the breakout profit potential of some of these companies, the current prices look outrageously low.

So today, we're giving you three undervalued biotech picks, so you can capitalize on the market's blind spot... and one of them could easily soar more than 200%.

When you see why their shares are down, it's clear why it's created such a great buy-in point...

What the Market Gets Wrong About the Biotech Sector

Fears about patents running out, pipeline drugs being delayed, trade war implications, and pressures on high drug prices are among the factors driving biotech down right now.

But a drop in price is not always reflective of a company's health.

In March, for example, AbbVie Inc. (NYSE: ABBV) plunged 14% in two days after it revealed disappointing phase 2 results for Rova-T. It was one of more than 50 drugs in AbbVie's pipeline. But the market treated it like a deal-breaker.

"When it comes to biotech, Wall Street tends to overreact," says Money Morning Defense and Tech Specialist Michael Robinson. "Investors have been conditioned to punish the sector and its stocks whenever the opportunity presents itself."

It won't last.

Michael says three critical factors will drive the value of the industry as a whole:

US Demographics

  1. Aging America: The oldest of the 65 million American baby boomers have entered their 70s. The more this demographic enters old age, the more reliant we as a population will become on all kinds of pharmaceuticals developed by biotech firms.
  2. Buyout Bonanza: Mergers and acquisitions in the healthcare sector surged 27%, to $332 billion, in 2017. Analysts at Bain & Co. expect that rising trend to continue in 2018. We've already seen $47 billion in M&A activity in the biotech sector in the first quarter of this year, 16% higher than the same quarter in 2017. And more big deals appear to be on the way, as we'll discuss further down.
  3. Better Politics: Though investors have anxiety over political pressure on drug companies, it appears to be unwarranted. In fact, the most significant move from Washington affecting biotech firms has been the speeding up of the FDA approval process. That's only going to be a positive for the industry.

"The biotech industry is clearly headed for better days," says Michael. "Not just in 2018, but well into the next decade."

With that in mind, we've selected three standout biotech stocks ready to pop.

Top Five: These tiny Canadian pot stocks are set to skyrocket. Click here...

All three of these stocks are growing earnings with remarkable consistency. They're trading well below their market value. And each one of them has earned a top score on our Money Morning Stock VQScore™ system, indicating they are giving us an excellent point to buy in.

Undervalued Biotech Stocks, No. 3

Join the conversation. Click here to jump to comments…

Stephen MackStephen Mack

About the Author

Browse Stephen's articles | View Stephen's research services

Stephen Mack has been writing about economics and finance since 2011. He contributed material for the best-selling books Aftershock and The Aftershock Investor. He lives in Baltimore, Maryland.

… Read full bio

Login
guest
guest
0 Comments
Inline Feedbacks
View all comments
LIVE
Visit Money Morning Live


Latest News

January 19, 2023 • By Money Morning Stock Research Team

These Stocks Could Go To $0

January 9, 2023 • By Money Morning Stock Research Team

The Government Is Pouring $391 Billion Into These Stocks - Buy Now

December 27, 2022 • By Money Morning Staff Reports

6 IPOs in 2023 You Can’t Afford to Miss
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Profit Takeover This Is VWAP Penny Hawk Trading Today Midday Momentum Pump Up the Close
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Night Trader Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Extreme Profit Hunters Profit Revolution Warlock's World Penny Nation Quantum Data Profits Live Trading Alliance Trade The Close Inside Money Trader Expiration Trader Vega Burst Trader Flashpoint Trader Darknet Hyper Momentum Trader

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell My Info

wpDiscuz